177 related articles for article (PubMed ID: 31262183)
1. Augment of Oxidative Damage with Enhanced Photodynamic Process and MTH1 Inhibition for Tumor Therapy.
Hu JJ; Chen Y; Li ZH; Peng SY; Sun Y; Zhang XZ
Nano Lett; 2019 Aug; 19(8):5568-5576. PubMed ID: 31262183
[TBL] [Abstract][Full Text] [Related]
2. Delivery of MutT homolog 1 inhibitor by functionalized graphene oxide nanoparticles for enhanced chemo-photodynamic therapy triggers cell death in osteosarcoma.
Huang X; Chen J; Wu W; Yang W; Zhong B; Qing X; Shao Z
Acta Biomater; 2020 Jun; 109():229-243. PubMed ID: 32294550
[TBL] [Abstract][Full Text] [Related]
3. Platinum-based nanocomposites loaded with MTH1 inhibitor amplify oxidative damage for cancer therapy.
Song Q; Yang W; Deng X; Zhang Y; Li J; Xing X; Chen W; Liu W; Hu H; Zhang Y
Colloids Surf B Biointerfaces; 2022 Oct; 218():112715. PubMed ID: 35932557
[TBL] [Abstract][Full Text] [Related]
4. MTH1 inhibitor amplifies the lethality of reactive oxygen species to tumor in photodynamic therapy.
Zhao L; Li J; Su Y; Yang L; Chen L; Qiang L; Wang Y; Xiang H; Tham HP; Peng J; Zhao Y
Sci Adv; 2020 Mar; 6(10):eaaz0575. PubMed ID: 32181355
[TBL] [Abstract][Full Text] [Related]
5. AuNP flares-capped mesoporous silica nanoplatform for MTH1 detection and inhibition.
Gao W; Cao W; Sun Y; Wei X; Xu K; Zhang H; Tang B
Biomaterials; 2015 Nov; 69():212-21. PubMed ID: 26298289
[TBL] [Abstract][Full Text] [Related]
6. MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good?
Abbas HHK; Alhamoudi KMH; Evans MD; Jones GDD; Foster SS
BMC Cancer; 2018 Apr; 18(1):423. PubMed ID: 29661172
[TBL] [Abstract][Full Text] [Related]
7. Synergistic therapy of chemotherapeutic drugs and MTH1 inhibitors using a pH-sensitive polymeric delivery system for oral squamous cell carcinoma.
Li X; Li L; Huang Y; Liu B; Chi H; Shi L; Zhang W; Li G; Niu Y; Zhu X
Biomater Sci; 2017 Sep; 5(10):2068-2078. PubMed ID: 28744533
[TBL] [Abstract][Full Text] [Related]
8. MTH1 inhibition synergizes with ROS-inducing agents to trigger cervical cancer cells undergoing parthanatos.
Li C; Xue Y; Wu J; Zhang L; Yang T; Ai M; Han J; Zheng X; Wang R; Boldogh I; Ba X
Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167190. PubMed ID: 38657912
[TBL] [Abstract][Full Text] [Related]
9. MTH1 Inhibitor TH287 Suppresses Gastric Cancer Development Through the Regulation of PI3K/AKT Signaling.
Zhan D; Zhang X; Li J; Ding X; Cui Y; Jia J
Cancer Biother Radiopharm; 2020 Apr; 35(3):223-232. PubMed ID: 32077746
[No Abstract] [Full Text] [Related]
10. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.
Gad H; Koolmeister T; Jemth AS; Eshtad S; Jacques SA; Ström CE; Svensson LM; Schultz N; Lundbäck T; Einarsdottir BO; Saleh A; Göktürk C; Baranczewski P; Svensson R; Berntsson RP; Gustafsson R; Strömberg K; Sanjiv K; Jacques-Cordonnier MC; Desroses M; Gustavsson AL; Olofsson R; Johansson F; Homan EJ; Loseva O; Bräutigam L; Johansson L; Höglund A; Hagenkort A; Pham T; Altun M; Gaugaz FZ; Vikingsson S; Evers B; Henriksson M; Vallin KS; Wallner OA; Hammarström LG; Wiita E; Almlöf I; Kalderén C; Axelsson H; Djureinovic T; Puigvert JC; Häggblad M; Jeppsson F; Martens U; Lundin C; Lundgren B; Granelli I; Jensen AJ; Artursson P; Nilsson JA; Stenmark P; Scobie M; Berglund UW; Helleday T
Nature; 2014 Apr; 508(7495):215-21. PubMed ID: 24695224
[TBL] [Abstract][Full Text] [Related]
11. Validation and development of MTH1 inhibitors for treatment of cancer.
Warpman Berglund U; Sanjiv K; Gad H; Kalderén C; Koolmeister T; Pham T; Gokturk C; Jafari R; Maddalo G; Seashore-Ludlow B; Chernobrovkin A; Manoilov A; Pateras IS; Rasti A; Jemth AS; Almlöf I; Loseva O; Visnes T; Einarsdottir BO; Gaugaz FZ; Saleh A; Platzack B; Wallner OA; Vallin KS; Henriksson M; Wakchaure P; Borhade S; Herr P; Kallberg Y; Baranczewski P; Homan EJ; Wiita E; Nagpal V; Meijer T; Schipper N; Rudd SG; Bräutigam L; Lindqvist A; Filppula A; Lee TC; Artursson P; Nilsson JA; Gorgoulis VG; Lehtiö J; Zubarev RA; Scobie M; Helleday T
Ann Oncol; 2016 Dec; 27(12):2275-2283. PubMed ID: 27827301
[TBL] [Abstract][Full Text] [Related]
12. Delivery of MTH1 inhibitor (TH287) and MDR1 siRNA via hyaluronic acid-based mesoporous silica nanoparticles for oral cancers treatment.
Shi XL; Li Y; Zhao LM; Su LW; Ding G
Colloids Surf B Biointerfaces; 2019 Jan; 173():599-606. PubMed ID: 30352381
[TBL] [Abstract][Full Text] [Related]
13. Adaptation to Chronic-Cycling Hypoxia Renders Cancer Cells Resistant to MTH1-Inhibitor Treatment Which Can Be Counteracted by Glutathione Depletion.
Hansel C; Hlouschek J; Xiang K; Melnikova M; Thomale J; Helleday T; Jendrossek V; Matschke J
Cells; 2021 Nov; 10(11):. PubMed ID: 34831264
[TBL] [Abstract][Full Text] [Related]
14. Carrier Free Photodynamic Synergists for Oxidative Damage Amplified Tumor Therapy.
Li XY; Deng FA; Zheng RR; Liu LS; Liu YB; Kong RJ; Chen AL; Yu XY; Li SY; Cheng H
Small; 2021 Oct; 17(40):e2102470. PubMed ID: 34480417
[TBL] [Abstract][Full Text] [Related]
15. The presumed MTH1-inhibitor TH588 sensitizes colorectal carcinoma cells to ionizing radiation in hypoxia.
Pompsch M; Vogel J; Classen F; Kranz P; Iliakis G; Riffkin H; Brockmeier U; Metzen E
BMC Cancer; 2018 Nov; 18(1):1190. PubMed ID: 30497423
[TBL] [Abstract][Full Text] [Related]
16. Inhibitor development of MTH1 via high-throughput screening with fragment based library and MTH1 substrate binding cavity.
Peng C; Li YH; Yu CW; Cheng ZH; Liu JR; Hsu JL; Hsin LW; Huang CT; Juan HF; Chern JW; Cheng YS
Bioorg Chem; 2021 May; 110():104813. PubMed ID: 33774493
[TBL] [Abstract][Full Text] [Related]
17. TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model.
Moukengue B; Brown HK; Charrier C; Battaglia S; Baud'huin M; Quillard T; Pham TM; Pateras IS; Gorgoulis VG; Helleday T; Heymann D; Berglund UW; Ory B; Lamoureux F
EBioMedicine; 2020 Mar; 53():102704. PubMed ID: 32151797
[TBL] [Abstract][Full Text] [Related]
18. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy.
Huber KV; Salah E; Radic B; Gridling M; Elkins JM; Stukalov A; Jemth AS; Göktürk C; Sanjiv K; Strömberg K; Pham T; Berglund UW; Colinge J; Bennett KL; Loizou JI; Helleday T; Knapp S; Superti-Furga G
Nature; 2014 Apr; 508(7495):222-7. PubMed ID: 24695225
[TBL] [Abstract][Full Text] [Related]
19. Identification of potent and selective MTH1 inhibitors.
Petrocchi A; Leo E; Reyna NJ; Hamilton MM; Shi X; Parker CA; Mseeh F; Bardenhagen JP; Leonard P; Cross JB; Huang S; Jiang Y; Cardozo M; Draetta G; Marszalek JR; Toniatti C; Jones P; Lewis RT
Bioorg Med Chem Lett; 2016 Mar; 26(6):1503-1507. PubMed ID: 26898335
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a new class of MTH1 inhibitor by X-ray crystallographic screening.
Yokoyama T; Kitakami R; Mizuguchi M
Eur J Med Chem; 2019 Apr; 167():153-160. PubMed ID: 30771603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
